<DOC>
	<DOCNO>NCT01203787</DOCNO>
	<brief_summary>Open-label study evaluate safety tolerability Sorafenib dose ramp-up ( start low dose gradually increase dose ) versus standard Sorafenib dosing subject unresectable and/or metastatic hepatocellular carcinoma .</brief_summary>
	<brief_title>Sorafenib Dose Ramp-Up Hepatocellular Carcinoma ( HCC )</brief_title>
	<detailed_description>This open-label study investigates impact dose ramp-up strategy sorafenib patient HCC . Clinical trial post-marketing data suggest sorafenib dose reduction discontinuation due adverse event common limit drug 's effectiveness . It hypothesis dose escalation strategy sorafenib improve tolerability allow great percentage patient remain drug . The primary end-point study total accumulated median daily dose sorafenib deliver month 2 4 .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>HCC must unresectable and/or metastatic CPT score &lt; 9 time screening ( Child A Child B score 7 8 ) Age 2075 year Signed informed consent EGD variceal screen perform per standard care prophylaxis nonselective betablockers ligation ECOG Performance Status â‰¤ 2 . Adequate bone marrow , liver renal function assess follow : 1 . Hemoglobin &gt; 8.5 g/dl 2 . Absolute neutrophil count ( ANC ) &gt; 1,500/mm3 3 . Platelet count &gt; 50,000/mm3 4 . Total bilirubin &lt; 3 mg/dl 5 . ALT AST ( &lt; 5 x ULN ) 6 . Creatinine &lt; 1.5 time ULN Women childbearing potential must negative serum pregnancy test perform within 7 day prior start treatment Women childbearing potential nonsurgically sterile men must agree use adequate contraception ( barrier method birth control ) prior study entry duration study participation . Men use adequate birth control least three month last administration sorafenib . Ability understand willingness sign write informed consent . A sign informed consent must obtain prior study specific procedure . INR &lt; 2.3 . Patients receive anticoagulation treatment agent warfarin heparin may allow participate . For patient warfarin , INR measure prior initiation sorafenib monitor least weekly , define local standard care , INR stable . Life expectancy least 24 week Absence inform consent ChildPugh score &gt; 9 ECOG PS &gt; 2 Active alcohol dependence per PI discretion History organ bone marrow transplant Plans relocate study center within period trial Pregnancy breastfeeding Contraindications sorafenib 1 . Cardiac disease : Congestive heart failure &gt; class II NYHA . Patients must unstable angina ( anginal symptom rest ) new onset angina ( begin within last 3 month ) myocardial infarction within past 6 month . 2 . Cardiac ventricular arrhythmia require antiarrhythmic therapy . 3 . Known brain metastasis . Patients neurological symptom must undergo CT scan/MRI brain exclude brain metastasis . 4 . Uncontrolled hypertension define systolic blood pressure &gt; 150 mmHg diastolic pressure &gt; 90 mmHg , despite optimal medical management . Known human immunodeficiency virus ( HIV ) infection Active clinically serious infection &gt; CTCAE Grade 2 . Thrombolic embolic event cerebrovascular accident include transient ischemic attack within past 6 month . Bleeding 1 . Pulmonary hemorrhage/bleeding event &gt; CTCAE Grade 2 within 4 week first dose study drug . 2 . Any hemorrhage/bleeding event &gt; CTCAE Grade 3 within 4 week first dose study drug . 3 . Evidence history bleed diathesis coagulopathy Serious nonhealing wound , ulcer , bone fracture . Major surgery , open biopsy significant traumatic injury within 4 week prior first study drug . Use St. John 's Wort rifampin ( rifampicin ) . Known suspected allergy sorafenib agent give course trial . Any condition impair patient 's ability swallow whole pill . Any malabsorption problem .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Hepatocellular Carcinoma</keyword>
	<keyword>HCC</keyword>
	<keyword>Liver Cancer</keyword>
</DOC>